Kris P Antonsen

US Patent:

6391452, May 21, 2002

Filed:

Jul 17, 1998

Appl. No.:

09/118463

Inventors:

Kris P. Antonsen - Berkeley CA
Rajiv Nayar - Richmond CA
Wei Wang - Alameda CA
Margaret Caudle - Alameda CA
Michael A. Shearer - Fairfield CA
Neville M. Concessio - San Francisco CA

Assignee:

Bayer Corporation - Pittsburgh PA

International Classification:

B32B 1502

US Classification:

4284022, 4272133, 42721331, 42721335, 264 41, 264 43, 264 46

Abstract:

The present invention relates to pharmaceutical compositions for delivery of drugs intended to reside in the nose, compositions for nasal administration of drugs, e. g. , antiviral agents, and particularly antiviral agents comprising the human major rhinovirus receptor, also known as intercellular adhesion molecule-1 (ICAM-1); to methods of making said nasal drug compositions, and to an improved process for the removal of residual solvent from pharmaceutical matrices.

US Patent:

6525176, Feb 25, 2003

Filed:

Jul 7, 2000

Appl. No.:

09/612592

Inventors:

Vivian W. Lee - Alamo CA
Kris P. Antonsen - Berkeley CA

Assignee:

PPL (Holdings) Limited - London

International Classification:

C07K 100

US Classification:

530350, 530413, 530416, 530380, 530392, 530395, 530830

Abstract:

A method for purifying human or other alpha-l proteinase inhibitor ( -PI) from a solution (which may be derived from the milk of a transgenic animal expressing the -PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg- -PI contaminants to the substrate while not substantially binding tg -PI to the substrate. Using the preferred embodiment, the purified tg -PI contains as little as 40 pg non- -PI-whey protein per mg total protein.

US Patent:

20130039898, Feb 14, 2013

Filed:

Feb 3, 2011

Appl. No.:

13/576625

Inventors:

Augustus O. Okhamafe - Concord CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - Novato CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - NOVATO CA

International Classification:

A61K 38/51
A61P 3/00
A61P 7/00
C12N 9/88

US Classification:

424 945, 435232

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

61945536, Feb 27, 2001

Filed:

Mar 9, 1998

Appl. No.:

9/036796

Inventors:

Vivian W. Lee - Alamo CA
Kris P. Antonsen - Berkeley CA

Assignee:

PPL Therapeutics (Scotland) Limited - Edinburgh

International Classification:

C07K 118
C07K 122

US Classification:

530413

Abstract:

A method for purifying human or other alpha-1 proteinase inhibitor (. alpha. sub. 1 -PI) from a solution (which may be derived from the milk of a transgenic animal expressing the. alpha. sub. 1 -PI) which comprises contacting the solution with a cation exchange substrate under conditions sufficient to bind non-tg-. alpha. sub. 1 -PI contaminants to the substrate while not substantially binding tg. alpha. sub. 1 -PI to the substrate. Using the preferred embodiment, the purified tg. alpha. sub. 1 -PI contains as little as 40 pg non-. alpha. sub. 1 -PI-whey protein per mg total protein.

US Patent:

20190345475, Nov 14, 2019

Filed:

Jan 11, 2019

Appl. No.:

16/246300

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

Assignee:

BIOMARIN PHARMACEUTICAL INC. - Novato CA

International Classification:

C12N 9/88
A61K 47/60
A61K 9/00
C07K 1/14
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.

US Patent:

20160362675, Dec 15, 2016

Filed:

Apr 15, 2016

Appl. No.:

15/130694

Inventors:

- Novato CA, US
Sean M. Bell - Novato CA, US
G. Nick Zecherle - Novato CA, US
Kris Antonsen - San Rafael CA, US
Yanhong Zhang - San Rafael CA, US
Kieu Ly Tran - San Francisco CA, US
Paul A. Fitzpatrick - Berkeley CA, US
Emil D. Kakkis - San Rafael CA, US
Michel Claude Vellard - San Rafael CA, US
Daniel J. Wendt - Walnut Creek CA, US
Mubarack Muthalif - Novato CA, US

International Classification:

C12N 9/88
A61K 47/48
A61K 38/51

Abstract:

Provided herein are phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. Further provided are compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, formulation, and use of such compositions for industrial and therapeutic purposes, e.g., treating hyperphenylalaninemia, including phenylketonuria, and other disorders, including cancer.